SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01096368

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years

This partially randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.

NCT01096368 Anaplastic Ependymoma Brain Ependymoma Cellular Ependymoma Clear Cell Ependymoma Ependymoma Papillary Ependymoma
MeSH:Ependymoma
HPO:Ependymoma

8 Interventions

Name: 3-Dimensional Conformal Radiation Therapy

Description: Patients undergo conformal radiotherapy
Type: Radiation
Group Labels: 2

Arm II (radiotherapy, chemotherapy) Arm III (radiotherapy, observation)

Name: Carboplatin

Description: Given IV
Type: Drug
Group Labels: 1

Arm I (radiotherapy, chemotherapy)

Name: Cisplatin

Description: Given IV
Type: Drug
Group Labels: 1

Arm II (radiotherapy, chemotherapy)

Name: Clinical Observation

Description: Patients undergo observation
Type: Other
Group Labels: 1

Arm III (radiotherapy, observation)

Name: Cyclophosphamide

Description: Given IV
Type: Drug
Group Labels: 2

Arm I (radiotherapy, chemotherapy) Arm II (radiotherapy, chemotherapy)

Name: Etoposide

Description: Given IV
Type: Drug
Group Labels: 2

Arm I (radiotherapy, chemotherapy) Arm II (radiotherapy, chemotherapy)

Name: Laboratory Biomarker Analysis

Description: Optional correlative studies
Type: Other
Group Labels: 3

Arm I (radiotherapy, chemotherapy) Arm II (radiotherapy, chemotherapy) Arm III (radiotherapy, observation)

Name: Vincristine

Description: Given IV
Type: Drug
Group Labels: 2

Arm I (radiotherapy, chemotherapy) Arm II (radiotherapy, chemotherapy)


Primary Outcomes

Description: Using Kaplan-Meier curves to estimate the observed EFS for the two randomization arms (post-radiation maintenance arm and post-radiation observation only arm). Log rank tests will be used to compare the observed EFS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups. If outcome data on ACNS0121 or this study suggest a difference or a different pattern in outcome between the 2 randomization strata, the primary analyses will be supplemented with log-rank tests performed separately in each stratum in order not to confound the overall conclusions of the study with respect to the effect of maintenance therapy.

Measure: Event-free survival (EFS)

Time: From first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause, assessed up to 5 years

Description: Using Kaplan-Meier curves to estimate the observed OS for the two randomization arms (post-radiation Maintenance arm and post-radiation Observation only arm). Log rank tests will be used to compare the observed OS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups. If outcome data on ACNS0121 or this study suggest a difference or a different pattern in outcome between the 2 randomization strata, the primary analyses will be supplemented with log-rank tests performed separately in each stratum in order not to confound the overall conclusions of the study with respect to the effect of maintenance therapy.

Measure: Overall survival (OS)

Time: From the time of randomization to death, assessed up to 5 years

Secondary Outcomes

Description: Kaplan-Meier curves will be used to estimate the EFS for patients who were non-randomly assigned to receive maintenance chemotherapy after incomplete resection

Measure: Event free survival (EFS) of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by post-operative induction chemotherapy or by second surgery

Time: Up to 5 years

Description: Kaplan-Meier curves will be used to estimate the OS for patients who were non-randomly assigned to receive maintenance chemotherapy after incomplete resection

Measure: Overall survival (OS) of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by post-operative induction chemotherapy or by second surgery

Time: Up to 5 years

Description: Estimated using Kaplan-Meier curves for patients with supratentorial classic disease that achieve complete resection or CR to induction chemotherapy and are assigned to observation only.

Measure: Event free survival (EFS) of children with supratentorial classic ependymoma who achieve complete resection at first or second surgery or children who achieve complete response (CR) after induction chemo assigned to observation

Time: Up to 5 years

Description: Estimated using Kaplan-Meier curves for patients with supratentorial classic disease that achieve complete resection or CR to induction chemotherapy and are assigned to observation only.

Measure: Overall survival (OS) of children with supratentorial classic ependymoma who achieve complete resection at first or second surgery or children who achieve complete response (CR) after induction chemo assigned to observation

Time: Up to 5 years

Description: Will be observed.

Measure: Neurologic, neuropsychological, and endocrine long-term sequelae of surgery, conformal radiotherapy, and maintenance chemotherapy

Time: At 9, 30, and 60 months post diagnosis

Description: Will be observed.

Measure: Gene expression signatures and genomic alterations in pediatric ependymoma

Time: At the time of first or second surgery

Description: Descriptive statistics will be used to summarize the various telomere maintenance measures. Log rank tests and multivariate Cox proportional hazards models will be used to explore the association between a telomere maintenance measurement and EFS/OS, with potential adjustments for the effects of other possible prognostic factors. Reliability of human telomerase reverse transcriptase (hTERT) immunohistochemistry results versus telomeric repeat amplification protocol (TRAP) assay results will be calculated using the kappa statistic.

Measure: Telomere maintenance

Time: Up to 5 years

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 K27M

V. To evaluate biologic prognostic factors in childhood ependymoma by studying molecular groups as defined by deoxyribonucleic acid (DNA) methylation profiling and immunohistochemistry, copy number variants to identify 1q gain in posterior fossa ependymomas, CDKN2A loss (homozygous deletion) in supratentorial ependymomas and specific genetic alterations such as RELA fusions, YAP1 fusions and the H3 K27M mutation on initial tumor samples and correlating these data with clinical outcome. --- K27M ---



HPO Nodes


HPO: